Blood Journal-Long-term prognostic significance of early molecular response to imatinib

 an analysis from the international randomized study of interferon versus STI571 (IRIS)

Timothy P. Hughes1,*, Andreas Hochhaus2, Susan Branford3,Martin C. Müller4, Jaspal S. Kaeda5, Letizia Foroni6,Brian J. Druker7, François Guilhot8, Richard A. Larson9,Stephen G. O'Brien10, Marc S. Rudoltz11, Manisha Mone11,Elisabeth Wehrle12, Vijay Modur13, John M. Goldman6 andJerald P. Radich14

1 Department of Haematology, SA Pathology, Royal Adelaide Hospital, Adelaide, SA, Australia; 2 Abt. Haematologie und internistische Onkologie, Klinik fuer Innere Medizin II, Universitaetsklinikum Jena, Jena, Germany; 3 Molecular Pathology, SA Pathology, Adelaide, Australia and School of Medicine, University of Adelaide, Adelaide, SA, Australia; 4 III. Medizinische Klinik, Medizinische Fakultaet Mannheim der Universitaet Heidelberg, Mannheim, Germany; 5 Department of Hematology, Central Hospital of Coimbra, Coimbra, Portugal; 6 Haematology Department, Hammersmith Hospital, London, United Kingdom; 7 Knight Cancer Institute, Oregon Health & Science University, Portland, OR, United States; 8 CIC INSERM, CHU de Poitiers, Poitiers, France; 9 University of Chicago, Chicago, IL, United States; 10Newcastle University Medical School, Newcastle, United Kingdom; 11 Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States; 12 Novartis Pharma AG, Basel, Switzerland; 13 Novartis Institute of Biomedical Research, Cambridge, MA, United States; 14 Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States

* Corresponding author; email: timothy.hughes@health.sa.gov.au

Abstract

http://bloodjournal.hematologylibrary.org/cgi/content/abstract/blood-2010-03-273979v1